NSEGeneral Updates21 Aug 2026 · 21 Aug 2026, 03:34 pm
General Updates
Aurobindo Pharma Limited · AUROPHARMA
✦ AI Summary▲ PositiveRegulatory
Aurobindo Pharma Limited has informed the Exchange about the completion of a US FDA inspection at Auro Peptides Ltd, a subsidiary/business arm of the Company. The inspection concluded with only one observation, relating to facility and equipment maintenance, and corrective action was initiated during the inspection. The Company reaffirmed its commitment to maintaining robust quality and compliance standards across its manufacturing facilities.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Auro Peptides Ltd, a subsidiary/business arm of the Company.
Attachments (1)
📄pdf
Download →
AUROPHARMA_21082026153316_LtrToSEsAuroPeptideUSFDA21082026.pdf
View document text
August 21, 2026
To To
Listing Department, The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED
Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,
MUMBAI -400 051 MUMBAI -400 001
Company Code No. AUROPHARMA Company Code No. 524804
Dear Sir / Madam,
Sub: Completion of US FDA Inspection at Auro Peptides Ltd, a subsidiary/business arm of the Company.
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this
is to inform you that:
The United States Food and Drug Administration (US FDA) conducted a routine inspection at AuroPeptides
Ltd, a manufacturer of Peptide APIs, located at Indrakaran Village, Kandi Mandal, Sangareddy District,
Telangana - 502329, from 17th to 21st August, 2026.
We are pleased to inform you that the inspection concluded with only one (1) observation, relating to
facility and equipment maintenance. This observation does not pertain to data integrity or related GMP
compliance. Corrective action was already initiated during the course of the inspection, and our formal
response will be submitted within the stipulated timeline.
This outcome reaffirms the Company's continued commitment to maintaining robust quality and
compliance standards across its manufacturing facilities.
The Company will keep the Stock Exchanges informed of any further developments in this regard, as
required under the applicable regulations.
Please take the above information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
B. Adi Reddy
Company Secretary
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com